







Calls Underpriced in Medical Device Leader with Catalyst into Year-End

TRADE SNAPSHOT

TICKER	MDT
SECURITY	Medtronic PLC
SECTOR	Healthcare – Medical Devices
CURRENT PRICE	\$122.50
LONG/SHORT	Long
TARGET	\$117
STOP	\$128
TIMEFRAME	2 Months

Trading Strategy: Long **MDT** December \$125 Calls at \$2.80 or Better

Net Debit/Credit: Debit of \$2.80

Profitability Zone: MDT Above \$127.80 on December OpEx

Options Volatility / Trade Simulator View:





Technical Analysis: MDT shares have pulled back to test a former resistance level that is now key support and also VWAP off the October lows while trapped just under its 200-day moving average this week. MDT weekly RSI is at an oversold level that it has historically rebounded.



Fundamental Analysis: MDT has a market cap of \$163B and trades 19.5X Earnings, 5.15X Sales and yields a 2%+ dividend while revenues seen growing 9.5% in 2022 with 25.5% EBITDA growth. MDT has four operating and reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services: the Cardiovascular Portfolio, the Medical Surgical Portfolio, the Neuroscience Portfolio, and the Diabetes Operating Unit. The Cardiovascular Portfolio is made up of the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio is made up of the Surgical Innovations and Respiratory, Gastrointestinal, & Renal divisions. The Neuroscience Portfolio is made up of the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. The Diabetes Operating Unit develops, manufactures, and markets products and services for the management of Type 1 and Type 2 diabetes. MDT had a recent set-back as its ONMED study did not meet the benefit threshold and resulted in a one-year delay and reducing expectations for it to \$500M+ by 2026 from \$1B. MDT has a very strong balance sheet and cash flows and could be in a position to utilize M&A to boost its growth profile. One report recently suggested MDT coulf target Triple Jump which makes an insulin patch pump to boost MDT's struggling diabetes unit. MDT is coming off a solid quarter with margins back to 2020 levels. Analysts have an average target of \$145 with short interest low at 0.7% of the float. Argus raised its target to \$165 after the latest report.

Options Activity:

Date =	Description Y	Volum∈ =	Open.ln =	Price =	Delta =	Impl Vo =	Prob.ITN =	Premium Pai: ऱ	Symbol =	Current Price =	Current OI =	Price Change =
10/21/2021	MDT 100 17 DEC 21 125 CALL	1,067	650	\$2.70	0.38	21.99%	34,71%	\$288,090	.MDT211217C125	\$3.55		31,48%
	MDT 100 (Weeklys) 3 DEC 21 124 CALL	601	0	\$3.00	0.4	20.71%	36.79%			\$3.00		0.00%
10/15/2021	MDT 100 (Weeklys) 5 NOV 21 127 CALL	1,184	116	\$2.81	0.52	22.59%	49.75%	\$338,624	.MDT211105C127	\$0.55	1248	-80.43%
10/11/2021	MDT 100 17 DEC 21 130 CALL	902	118	\$2.45	0.313	23.81%	27.85%	\$220,990	.MDT211217C130	\$1.75	2131	-28.57%
10/4/2021	MDT 100 (Weeklys) 12 NOV 21 128 CALL	4,028	0	\$2.86	0.353	19.05%	33.00%	\$1,152,008	.MDT211112C128	\$0.48	2784	-83.22%
9/30/2021	MDT 100 19 NOV 21 130 CALL	7,947	4,379	\$2.68	0.348	24.30%	31.54%	\$2,129,796	.MDT211119C130	\$0.65	16040	-75.75%
9/30/2021	MDT 100 19 NOV 21 125 PUT	5,592	1,866	\$4.10	-0.481	23.60%	51.71%	\$2,292,720	.MDT211119P125	\$3.00	13006	-26.83%
9/28/2021	MDT 100 21 JAN 22 120 CALL	2,042	3,639	\$10.10	0.65	24.68%	59.39%	\$2,062,420	.MDT220121C120	\$7.49	3709	-25.84%
9/15/2021	MDT 100 17 JUN 22 130 PUT	800	128	\$9.95	-0.46	20.99%	54.40%	\$808,000	.MDT220617P130	\$13.78	984	38.49%
8/18/2021	MDT 100 18 FEB 22 150 CALL	1,070	18	\$1.45	0.2	23.43%	16.14%	\$337,050	.MDT220218C150	\$0.39	1256	-73.10%
7/27/2021	MDT 100 19 NOV 21 135 PUT	535	112	\$9.00	-0.63	19.07%	67.51%	\$484,175	.MDT211119P135	\$11.75	894	30.56%
7/27/2021	MDT 100 17 JUN 22 120 CALL	275	57	\$16.30	0.66	23.61%	57.09%	\$448,250	.MDT220617C120	\$9.60	428	-41.10%
6/18/2021	MDT 100 17 JUN 22 125 CALL	403	178	\$9.65	0.487	23.03%	39.54%	\$388,895	.MDT220617C125	\$7.81	1648	-19.07%
6/11/2021	MDT 100 21 JAN 22 125 CALL	1,600	1,377	\$7.80	0.5	22.25%	42.86%	\$1,272,000	.MDT220121C125	\$4.55	2976	-41.67%

Potential Catalysts: Earnings 11-23

Disclaimer:

Not Investment Advice or Recommendation

Any descriptions "to buy", "to sell", "long", "short" or any other trade related terminology should not be seen as a recommendation. The Author may or may not take positions in any of the names mentioned, and is not obligated to disclose positions, nor position sizes.

Content is for informational and educational purposes only, and is not to be construed as specific investment advice or recommendations. You alone will need to evaluate the merits and risks associated with the use of this content. Decisions based on information provided are your sole responsibility, and before making any decision on the basis of this information, you should consider (with or without the assistance of a financial and/or securities adviser) whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. Investors should seek qualified professional financial advice regarding the suitability of investing in any securities or following any investment strategies.

No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security. Nothing constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, OptionsHawk has not taken into account the investment needs, objectives and financial circumstances of any particular investor. This information does not consider the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors

For example, and, as always, be aware that market timing and conditions may materially affect trades of this nature: The above is an example of a trade idea, but you must be aware of the risks of trading. As we have disclosed, we are not licensed, and we are not giving specific securities advice for your portfolio. We are merely providing examples and education of strategies. We always advise people to get professional advice, and we are not recommending any particular trade or security, or soliciting any trade or security.